Weld Capital Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Weld Capital Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-575	Closed	-$140K	–	721
2020 Q3	$140K	Buy	+575	New	+$179K	0.06%	426
2020 Q1	–	Sell	-784	Closed	-$350K	–	768
2019 Q4	$350K	Buy	+784	New	+$278K	0.07%	433

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Weld Capital Management's EIGR Position: Q4 2020 in Review

Weld Capital Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2020, closing a stake of 575 shares — an estimated $140K sold.

Weld Capital Management first reported a position in EIGR in Q4 2019 and held it in 2 quarters. The position peaked at $350K in Q4 2019. 91 funds tracked by Wall St. Rank hold EIGR as of Q4 2020.

Weld Capital Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
Weld Capital Management sold 575 Eiger BioPharmaceuticals, Inc. shares in Q4 2020, an estimated $140K.
Weld Capital Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2019 and held it in 2 quarters.
Weld Capital Management's Eiger BioPharmaceuticals, Inc. position peaked at $350K in Q4 2019.
91 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2020.

Based on Weld Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.